Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the mainstay of treatment. However, immune checkpoint inhibitors are revolutionizing the treatment algorithm for this patient population with the 2016 / 2018 approvals of Merck & Co.’s Keytruda and Bristol-Myers Squibb / Ono Pharmaceutical’s Opdivo for previously treated recurrent or metastatic SCCHN. Although SCCHN has historically proved to be a complex challenge for drug developers, many immune-oncology approaches and other drug classes are competing in late-phase development for SCCHN, both in the metastatic setting and in earlier stages of the disease. Several agents are being positioned for the untapped and lucrative locoregionally advanced SCCHN setting and are also poised to contribute to the robust market growth over the 2018-2028 forecast period.
- How large
arethe clinically and commercially relevant drug-treatable SCCHN populations, and how willdrug-treatment rates change over time?
- What is the current state of treatment for recurrent or metastatic SCCHN? What are interviewed experts’ views on these therapies?
- Which pipeline products are poised to become options for the treatment of SCCHN, and what sales / uptake could they secure?
- What are the key drivers and constraints in the SCCHN market, and how will the major markets evolve over the ten-year forecast period?
Disease Landscape & Forecast provides